Fibrosis: Oncodesign and TiumBio sign collaboration agreement for R&D of drug candidates
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix® drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates. This initial phase of the collaboration will be funded by TiumBio.
Here is our April 2020 issue which details the new organization of the Group into 3 Business Units. Interviews and articles on the menu. Anatomy of the new face of Oncodesign: BU Service, BU Biotech & BU Artificial Intelligence.
Without forgetting the editorial by Ph. Genne entitled “how much is a human life worth”. “Behind any disaster, there is the promise of reconstruction and it is in this direction that we must look …”.
18 rue Jean Mazen - FR - 21000 Dijon Tel.+33 380 788 260